Skip to main content

Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.

Publication ,  Journal Article
Stafford-Smith, M; Lefrak, EA; Qazi, AG; Welsby, IJ; Barber, L; Hoeft, A; Dorenbaum, A; Mathias, J; Rochon, JJ; Newman, MF ...
Published in: Anesthesiology
August 2005

BACKGROUND: Hemodynamic protamine reactions with heparin reversal during cardiac surgery are common and associated with adverse outcomes. As an alternative to protamine, the authors examined heparinase I reversal of heparin after aortocoronary bypass graft surgery. METHODS: In a randomized, double-blind, double-dummy trial, 167 on- and off-pump aortocoronary bypass graft surgery patients received either heparinase I (maximum 35 microg/kg) or protamine (maximum 650 mg) for heparin reversal, monitored by activated clotting time values and clinical assessment. Hemodynamic parameters were recorded electronically; safety evaluation was to 30 days postoperatively. Noninferiority was predefined as 400 ml or less median 12-h chest tube drainage from intensive care unit arrival for heparinase I patients, after risk adjustment. Hemodynamic instability was defined as systemic hypotension (> or = 30 mmHg decrease) and/or pulmonary hypertension (> or = 40 mmHg with an increase > or = 10 mmHg) within 30 min of heparin reversal initiation. RESULTS: Patient enrollment was terminated on advisement of the Data Safety Monitoring Board. Although heparinase I was noninferior for 12-h chest tube drainage, protamine had a superior safety profile. Overall, heparinase I subjects had longer hospital stays (P = 0.04), were more likely to experience a serious adverse event (P = 0.01), and were less likely to avoid transfusion (P = 0.006). A composite morbidity score was not different (P = 0.24), and similar rates of hemodynamic instability were observed between groups. Findings were consistent in analyses stratified by on- and off-pump surgery. CONCLUSIONS: Heparinase I reverses heparin anticoagulation after aortocoronary bypass graft surgery but is not equivalent to protamine because of its inferior safety profile.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Anesthesiology

DOI

ISSN

0003-3022

Publication Date

August 2005

Volume

103

Issue

2

Start / End Page

229 / 240

Location

United States

Related Subject Headings

  • Protamines
  • Middle Aged
  • Male
  • Humans
  • Heparin Lyase
  • Heparin Antagonists
  • Female
  • Double-Blind Method
  • Coronary Artery Bypass
  • Cardiopulmonary Bypass
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Stafford-Smith, M., Lefrak, E. A., Qazi, A. G., Welsby, I. J., Barber, L., Hoeft, A., … Members of the Global Perioperative Research Organization, . (2005). Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology, 103(2), 229–240. https://doi.org/10.1097/00000542-200508000-00005
Stafford-Smith, Mark, Edward A. Lefrak, Anjum G. Qazi, Ian J. Welsby, Linda Barber, Andreas Hoeft, Alejandro Dorenbaum, et al. “Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.Anesthesiology 103, no. 2 (August 2005): 229–40. https://doi.org/10.1097/00000542-200508000-00005.
Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, et al. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology. 2005 Aug;103(2):229–40.
Stafford-Smith, Mark, et al. “Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass.Anesthesiology, vol. 103, no. 2, Aug. 2005, pp. 229–40. Pubmed, doi:10.1097/00000542-200508000-00005.
Stafford-Smith M, Lefrak EA, Qazi AG, Welsby IJ, Barber L, Hoeft A, Dorenbaum A, Mathias J, Rochon JJ, Newman MF, Members of the Global Perioperative Research Organization. Efficacy and safety of heparinase I versus protamine in patients undergoing coronary artery bypass grafting with and without cardiopulmonary bypass. Anesthesiology. 2005 Aug;103(2):229–240.

Published In

Anesthesiology

DOI

ISSN

0003-3022

Publication Date

August 2005

Volume

103

Issue

2

Start / End Page

229 / 240

Location

United States

Related Subject Headings

  • Protamines
  • Middle Aged
  • Male
  • Humans
  • Heparin Lyase
  • Heparin Antagonists
  • Female
  • Double-Blind Method
  • Coronary Artery Bypass
  • Cardiopulmonary Bypass